Foresight Diagnostics

Foresight Diagnostics Inc. is a precision medicine company dedicated to improving the lives of cancer patients through improved cancer detection methods. The company is developing a novel liquid biopsy test for the measurement of minimal residual disease (MRD) for aid in patient management. Foresight Diagnostics was founded in 2020 and is headquartered in Aurora, Colorado. The company's cell-free DNA testing platform was developed in the labs of two prominent professors at Stanford University and is backed by several major peer-reviewed publications. The latest milestone for Foresight Diagnostics was a $58.75M Series B investment received on 27 April 2023. This investment round was led by Pear Ventures, Civilization Ventures, Agent Capital, Bluebird Ventures, CU Healthcare Innovation Fund, Foresite Capital, and Stanford University. This funding reflects the significant partnering interest the company has garnered from multiple pharmaceutical companies in oncology, positioning it for rapid growth. As a precision medicine company in the biotechnology, health care, and pharmaceutical industries, Foresight Diagnostics holds significant promise in advancing cancer detection methods and enhancing patient management. With strong backing from leading diagnostics VC firms in Silicon Valley and its academic roots at Stanford University, the company is well-positioned to make a meaningful impact in cancer care.